Updated Data from JP28927 Study of Alectinib in ALK plus NSCLC Patients with or without History of ALK Inhibitor Treatment

被引：0
|
作者：
Hotta, Katsuyuki [1 ]
Hida, Toyoaki [2 ]
Nakagawa, Kazuhiko [3 ]
Seto, Takashi [4 ]
Satouchi, Miyako [5 ]
Nishio, Makoto [6 ]
Murakami, Haruyasu [7 ]
Ohe, Yuichiro [8 ]
Takeda, Koji [9 ]
Yoshimoto, Takuya [10 ]
Tanaka, Tomohiro [10 ]
Tamura, Tomohide [11 ]
机构：
[1] Okayama Univ Hosp, Okayama, Japan
[2] Aichi Canc Ctr, Nagoya, Aichi 464, Japan
[3] Kinki Univ, Fac Med, Osaka, Japan
[4] Kyushu Natl Canc Ctr, Fukuoka, Japan
[5] Hyogo Canc Ctr, Akashi, Hyogo, Japan
[6] Jfcr, Canc Inst Hosp, Tokyo, Japan
[7] Shizuoka Canc Ctr, Shizuoka, Japan
[8] Natl Canc Ctr, Tokyo, Japan
[9] Osaka City Gen Hosp, Osaka, Japan
[10] Chugai Pharmaceut Co Ltd, Tokyo, Japan
[11] St LukeS Int Hosp, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
Alectinib; ALK plus NSCLC; ALK Inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-020
引用
收藏
页码：S648 / S648
页数：1
相关论文
共 50 条
  • [21] Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK plus NSCLC
    Mok, T. S. K.
    Shaw, A. T.
    Camidge, R. D.
    Gadgeel, S. M.
    Rosell, R.
    Dziadziuszko, R.
    Kim, D-W.
    Perol, M.
    Ou, S-H.
    Bordogna, W.
    Smoljanovic, V.
    Hilton, M.
    Peters, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 607 - 607
  • [22] Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC
    Song, Lianxi
    Xu, Qinqin
    Lizaso, Analyn
    Zhang, Yongchang
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : 349 - 351
  • [23] OVERALL SURVIVAL ESTIMATES ADJUSTING FOR TREATMENT CROSSOVER IN PATIENTS PREVIOUSLY UNTREATED WITH AN ALK INHIBITOR WITH ALK plus NSCLC USING DATA FROM THE ALTA-1L CLINICAL TRIAL
    Cranmer, H.
    Liu, Y.
    Kay, S.
    Shen, J.
    VALUE IN HEALTH, 2020, 23 : S424 - S425
  • [24] Cost Analysis of the Management of CNS Metastases in Patients with Advanced ALK plus NSCLC: Alectinib vs Crizotinib
    Massuti, B.
    Lazaro, M.
    Isla, D.
    Gordo, R.
    Ruiz De Alda, L.
    Ortega, N.
    Oyaguez, I.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S856 - S856
  • [25] OVERALL SURVIVAL INDIRECT TREATMENT COMPARISON RESULTS ADJUSTED FOR TREATMENT CROSSOVER: BRIGATINIB RELATIVE TO ALECTINIB IN PATIENTS WITH ALK plus NSCLC PREVIOUSLY UNTREATED WITH AN ALK INHIBITOR USING THE FINAL RESULTS FROM ALTA-1L AND ALEX
    Cranmer, H.
    Lin, H. M.
    Kay, S.
    Cazzato, S.
    VALUE IN HEALTH, 2022, 25 (01) : S27 - S27
  • [26] Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC): Primary results from the J-ALEX study.
    Nokihara, Hiroshi
    Hida, Toyoaki
    Kondo, Masashi
    Kim, Young Hak
    Azuma, Koichi
    Seto, Takashi
    Takiguchi, Yuichi
    Jo, Makoto Nish
    Yoshioka, Hiroshige
    Imamura, Fumio
    Hotta, Katsuyuki
    Watanabe, Satoshi
    Goto, Koichi
    Nakagawa, Kazuhiko
    Mitsudomi, Tetsuya
    Yamamoto, Nobuyuki
    Kuriki, Hiroshi
    Asabe, Ryoichi
    Tanaka, Tomohiro
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK plus NSCLC in Japan
    Tamiya, M.
    Goto, Y.
    Kenmotsu, H.
    Kurata, T.
    Murakami, S.
    Yanagitani, N.
    Taniguchi, H.
    Kuyama, S.
    Shimizu, J.
    Yokoyama, T.
    Shimada, N.
    Maeda, T.
    Tamiya, A.
    Uchiyama, A.
    Imaizumi, K.
    Takahama, T.
    Nishio, M.
    Hayashi, H.
    Shiraiwa, N.
    Okura, M.
    Kikkawa, H.
    Thomaidou, D.
    Kato, T.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S456 - S457
  • [28] Symptoms and QOL with Ceritinib in ALK plus NSCLC Patients with/without Brain Metastases
    Crino, Lucio
    Ahn, Myung-Ju
    De Marinis, Filippo
    Groen, H. J. M.
    Wakelee, Heather A.
    Hida, Toyoaki
    Mok, Tony
    Shaw, Alice
    Felip, Enriqueta
    Nishio, Makoto
    Scagliotti, Giorgio V. V.
    Branle, Fabrice
    Emeremni, Chetachi
    Sutradhar, Santosh
    Quadrigli, Massimiliano
    Zhang, Jie
    Spigel, David
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S379 - S379
  • [29] BUDGET IMPACT ANALYSIS OF ALECTINIB FOR THE TREATMENT OF PATIENTS WITH UNTREATED ALK-REARRANGED NSCLC IN ITALY
    Bellone, M.
    Pradelli, L.
    Recchia, A.
    Caputo, A.
    Masetti, L.
    VALUE IN HEALTH, 2018, 21 : S28 - S28
  • [30] Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK plus NSCLC.
    Peters, Solange
    Mok, Tony S. K.
    Gadgeel, Shirish M.
    Rosell, Rafael
    Dziadziuszko, Rafal
    Kim, Dong-Wan
    Perol, Maurice
    Ou, Sai-Hong Ignatius
    Shaw, Alice Tsang
    Bordogna, Walter
    Smoljanovic, Vlatka
    Hilton, Magalie
    Ruf, Thorsten
    Archer, Venice Rosale
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345